Case Study: Dominantly Inherited Alzheimers Network (DIAN) Trials Unit

“XNAT CR passed industry audits with flying colors.”
Tammie Benzinger, MD, PhD, Director of Imaging, DIAN Trials Unit @ Washington University School of Medicine

The Dominantly Inherited Alzheimer Network (DIAN) clinical trials unit is running phase II/III trials of drugs developed by Eli Lilly and Roche to assess their efficacy in treating early onset Alzheimer’ disease, using imaging endpoints.

DIAN imaging data is collected at clinical sites around the world – in North America, Australia, Europe and soon in Asia and South America – and uploaded to XNAT CR using the built-in web-based upload tool. This imaging data is then routed to quality control reviewers at sites around the country. Radiologics worked with Dr. Tammie Benzinger, DIAN Imaging Core Leader, to customize XNAT CR data types, workflows, pipelines and reports for the DIAN TU protocol.

“XNAT CR’s 21 CFR Part 11 compliance, along with its customizability, were key factors in selecting a data management system for the DIAN trials,” says Dr. Benzinger.

XNAT CR manages the full imaging workflow from acquisition to quality control to image processing and analysis. Dr. Benzinger reports, “XNAT’s workflow and notification system ensures that data are quickly uploaded, reviewed, and processed seamlessly.”